Triastek advances 3D printed drug D23 - a delayed-release budesonide tablet produced using Triastek’s proprietary MED - for IgAN treatment.

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has ...

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent clinical study. D23 is budesonide ...

NANJING, China--(BUSINESS WIRE)--#3DPrintingPharmaceutical--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive ...

NANJING, China--(BUSINESS WIRE)--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent ...

Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN ...

Delays in receiving coverage for essential medications like insulin and albuterol can worsen symptoms, increase costs, and ...

If you're not happy with the results, please do another search.

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

The Society for Clinical Research Sites (SCRS) and Fortrea , a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward ...